Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $34.85 | Total: $174.25 |
| 1 | 10 | $29.52 | Total: $295.20 |
| 1 | 25 | $25.01 | Total: $625.25 |
| 1 | 50 | $21.32 | Total: $1,066.00 |
| 1 | 100 | $18.45 | Total: $1,845.00 |
Overview
BGT226 (NVP-BGT226) is a novel dual PI3KmTOR inhibitor, targeting PI3K ?, ?, and ? with IC50 values of 4 nM, 63 nM, and 38 nM, respectively.
Chemical Properties
| Molecular Formula | C28H25F3N6O2 |
| Molecular Weight | 534.53 |
| CAS Numbers | 915020-55-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Markman B , Tabernero J , Krop I , et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors[J]. Annals of Oncology Official Journal of the European Society for Medical Oncology, 2012, 23[9] 2399.